Parafibromin is the 531-amino-acid protein product encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal dominant hyperparathyroidism-jaw tumor familial cancer syndrome, sporadic parathyroid cancer, and a minority of families with isolated hyperparathyroidism. Parafibromin contains no identified functional domains but bears sequence homology to Cdc73p, a budding yeast protein component of the RNA polymerase II-associated Paf1 complex. This study addressed the expression and functional properties of human parafibromin. A survey of human and mouse tissues analysed with polyclonal antibodies to parafibromin showed specific immunoreactivity in adrenal and parathyroid glands, kidney, heart, and skeletal muscle. Subcellular fractionation and laser confocal microscopy of normal human parathyroid gland demonstrated expression of parafibromin in both the cytoplasmic and nuclear compartments. Parafibromin was expressed in four parathyroid adenomas but was absent from two parathyroid carcinomas. Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant implicated in parathyroid cancer and familial isolated hyperparathyroidism, inhibited cell proliferation, and blocked expression of cyclin D1, a key cell cycle regulator previously implicated in parathyroid neoplasia. These results demonstrate that human parafibromin is a nucleocytoplasmic protein with functions consistent with its postulated role as a tumor suppressor protein.
The gene for the hyperparathyroidism-jaw tumor syndrome (HPT-JT) was recently identified by positional cloning (Carpten et al., 2002) . HPT-JT is an autosomal dominant syndrome with high but incomplete penetrance (Jackson et al., 1990) . The major features are primary hyperparathyroidism (90%) including 15% of all affected by HPT-JT with parathyroid cancer, jaw tumors (30%), bilateral renal cysts (10%), and less commonly solid renal tumors (Jackson, 1958; Firat and Stutzman, 1968; Kennett and Pollick, 1971; Dinnen et al., 1977; Rosen and Palmer, 1981; Warnakulasuriya et al., 1985; Mallette et al., 1987; Jackson et al., 1990; Streeten et al., 1992; Visset et al., 1992; Wassif et al., 1993; Kakinuma et al., 1994; Inoue et al., 1995; Szabo et al., 1995; Teh et al., 1996 Teh et al., , 1998 Fujikawa et al., 1998; Yoshimoto et al., 1998; Cavaco et al., 2001; Simonds et al., 2002) . Nearly 10% of mutation carriers appear to remain clinically silent in adulthood (Teh et al., 1996; Simonds et al., 2002) . Germline inactivating HRPT2 mutation has also been reported in a minority of kindreds with familial isolated hyperparathyroidism (FIHP) (Carpten et al., 2002; Howell et al., 2003; Simonds et al., 2004; Villablanca et al., 2004) . Somatic inactivating mutation in HRPT2 was also recently described in the majority of sporadic parathyroid cancers (Howell et al., 2003; Shattuck et al., 2003) ; unexpected germline HRPT2 mutation was also found in some 30% of these patients (Shattuck et al., 2003) .
HRPT2 encodes parafibromin, a 531-amino-acid putative tumor suppressor protein. Parafibromin contains no known functional domains but demonstrates sequence homology to Cdc73p, a budding yeast protein component of the RNA polymerase II-associated Paf1 complex. Since little is known about human parafibromin, we investigated its expression and functional properties.
To study the expression of parafibromin, we generated polyclonal antibody NC190 in rabbit to a recombinant glutathione S-transferase (GST) fusion protein containing residues 2-135 of human parafibromin. The ability of NC190 to detect transfected AU5 epitope-tagged human parafibromin in COS-7 cells was compared to the AU5 monoclonal antibody (directed against the hexapeptide epitope TDFYLK; Lim et al., 1990) . Both antibodies, but not normal rabbit IgG, detected a B60 kDa band in COS-7 cells transfected with AU5-parafibromin but not in vector-transfected controls ( Figure 1a ). AU5-parafibromin-transfected COS cells were homogenized and separated into nuclear and cytosolic fractions. Transfected AU5-tagged wildtype parafibromin was found in both compartments (Figure 1b , middle panels). Additional evidence for the nuclear localization of parafibromin was provided by laser confocal microscopy (see below).
To assess the range of parafibromin expression, antibody NC190 was used to immunoblot various adult human and mouse tissue homogenates (Figure 2 ). Mouse parafibromin has 100% sequence identity to the human protein. Full-length human and mouse parafibromin was identified as a B60 kDa band present in the adrenal, heart, and kidney with a mobility nearly identical to epitope-tagged human parafibromin expressed in transfected COS cells. In mouse kidney, a 53 kDa NC190 immunoreactive band was also present. Mouse, but not human, liver and ovary also expressed the 60 kDa NC190-reactive band. In both human and mouse, the heart and skeletal muscle expressed prominent 40 kDa NC190-immunoreactive bands. No parafibromin immunoreactivity was found in the brain in either species. Preadsorption of NC190 antibodies with recombinant His6-tagged parafibromin 2-135 completely blocked the immunoreactivity of the 60, 53, and 40 kDa bands suggesting that all were parafibrominrelated proteins (Figure 2) .
We investigated the expression of parafibromin in human parathyroid gland because loss of parafibromin function has its most penetrant and morbid disease manifestations in this tissue. Strong immunoreactivity was seen in the parenchyma of normal human parathyroid by epifluorescence microscopy with NC190 but not with normal rabbit IgG suggesting that endogenous parafibromin is diffusely expressed throughout the parathyroid gland (Figure 3a-c) . Preadsorption of Analysis of endogenous parafibromin expression in human and mouse tissues. A measure of 50 mg of total human or mouse homogenate from the indicated tissues was analysed on 10-20% tricine gels by immunoblotting with the NC190 IgG fraction without (upper) or with (lower) preadsorption with a purified recombinant fusion protein containing residues 2-207 of the N56E mutant of mouse phosphoglycerokinase fused in-frame to residues 2-135 of human parafibromin and prepared in pQE-80L (Qiagen; gives a His6 tag to fusion protein). A, adrenal gland; B, brain; H, heart; K, kidney; L, liver; O, ovary; M, skeletal muscle (Human and Mouse Protein Medley, Clontech). Vector-and parafibromintransfected COS cell lysate as negative (À), and positive ( þ ) controls, respectively. Loading control anti-a-tubulin blot shown (middle). The relative migration of molecular weight markers is shown to the left of the blots NCI 90 with recombinant parafibromin 2-135 completely abrogated this immunofluorescence (not shown). Laser confocal microscopy of normal human parathyroid (Figure 3d-g ) stained with NC190 and the nuclear counterstain propidium iodide provided evidence for both the cytoplasmic (green in merged image Figure 3g ) and nuclear (yellow in merged image) localization of parafibromin. Subcellular fractionation also showed that endogenous parafibromin in the normal human parathyroid gland, like transfected parafibromin in COS cells, is found in both cytosolic and nuclear fractions (Figure 3h) .
A small number of human parathyroid tumors were also studied. Four benign sporadic parathyroid adenomas demonstrated the presence of parafibromin in NC190 immunoblots (Figure 3i ). In contrast, two parathyroid carcinomas showed no evidence of parafibromin expression by NC190 immunoblotting (Figure 3i ), a finding consistent with, and complementary to, two recent detailed molecular biologic analyses showing frequent biallelic HRPT2 inactivation in parathyroid cancers (Howell et al., 2003; Shattuck et al., 2003) . The tumor homogenates were also analysed for the expression of cyclin D1, an oncogene first implicated in the pathogenesis of parathyroid tumors (Arnold et al., 1991) and later recognized as a key regulatory protein in the cell cycle (Arnold et al., 2002) . Consistent with previous studies (Hsi et al., 1996; Vasef et al., 1999) , both parathyroid adenomas and carcinomas overexpressed cyclin D1 relative to normal parathyroid (Figure 3i ). The level of cyclin D1 overexpression was significantly greater in the two parathyroid cancers than in the adenomas (Figure 3i) .
Parafibromin is thought to be a tumor suppressor protein since disease-associated HRPT2 mutation uniformly predicts loss of parafibromin expression or function (Carpten et al., 2002; Howell et al., 2003; Shattuck et al., 2003; Simonds et al., 2004; Villablanca et al., 2004) . The action of many tumor suppressors and oncogenes important in endocrine clonal neoplasia involves dysregulation of one or more cell cycle checkpoint proteins (Pestell et al., 1999) . As a general screen for such function, we checked the growth of mouse NIH3T3 cells after transfection by wild-type For a-h human parathyroid gland was harvested from cadavers of patients with no apparent disorder of mineral metabolism at the time of death from unrelated causes. (i) Total homogenates of normal parathyroid gland, four benign sporadic parathyroid adenomas, and two parathyroid cancers were analysed for the expression of parafibromin (NC190), cyclin D1 (SC-20044, Santa Cruz), and a-tubulin by Western blot in two groups as shown. The cyclin D1 analysis was performed with all homogenates on a single blot. The mutation status of HRPT2 in the tumor DNA was not determined. All patient testing and tissue procurement were performed with informed consent under protocols approved by the NIDDK Institutional Review Board parafibromin or the L64P missense parafibromin mutant associated with parathyroid cancer and FIHP (Howell et al., 2003; Villablanca et al., 2004) . Wild-type parafibromin strongly inhibited NIH3T3 cell growth in a proliferation assay, while the L64P parafibromintransfected cells did not differ from control (Figure 4a) . Similar findings were obtained in transfected human HEK-293 cells (not shown).
As a result of the potent inhibition of cell growth in wild-type parafibromin-transfected cells, we checked the impact of parafibromin transfection on cyclin D1 expression. Wild-type parafibromin strongly inhibited the expression of cyclin D1, while the L64P parafibromin mutant was without effect in both NIH3T3 and HEK-293 cells (Figure 4b ). The failure of the L64P parafibromin mutant to inhibit cell proliferation and cyclin D1 expression was not due to lack of mutant parafibromin protein expression (Figure 4b ) or to grossly abnormal subcellular localization ( Figure 1b) .
We demonstrate here that the putative tumor suppressor protein parafibromin is expressed in the parathyroid and kidney, both tissues with known disease manifestations in HPT-JT (Jackson et al., 1990; Simonds et al., 2002) . The presence of parafibromin protein in benign but not malignant parathyroid tumor demonstrated here is consistent with recent work demonstrating frequent biallelic HRPT2 inactivation in parathyroid cancer but not adenoma (Howell et al., 2003; Shattuck et al., 2003) . However, analysis of a greater number of benign and malignant parathyroid tumors for parafibromin expression will be needed to confirm the findings presented here. We find that parafibromin is also expressed in other tissues, such as adrenal, heart and skeletal muscle, which are without known disease association with HRPT2 mutation. Understanding the disease specificity resulting from loss of function of widely expressed tumor suppressor proteins is an ongoing challenge not only for parafibromin, but also for other tumor suppressors such as menin (Marx, 2002) and Brcal (Elledge and Amon, 2002) . Whether the 40 kDa NC190-immunorective bands seen in the heart and skeletal muscle (and the 53 kDa band in mouse kidney) represent N-terminal proteolytic fragments of parafibromin or are the products of alternatively spliced HRPT2 transcripts will require further investigation. Preliminary blotting studies with a new C-terminaldirected antiparafibromin antibody fail to show the smaller bands in mouse tissues, consistent with the former explanation (not shown).
The antiproliferative properties of parafibromin and its ability to inhibit cyclin D1 expression demonstrated here suggest an obvious model for neoplasia resulting from loss of parafibromin function. The inhibitory effect of parafibromin on cyclin D1 expression would be lost upon biallelic HRPT2 inactivation, and in certain susceptible tissues, such as parathyroid, disinhibition of cyclin D1 expression could initiate neoplastic transformation (Arnold et al., 2002) . Despite the potent effect of parafibromin on cyclin D1 expression shown in the present study, it is not clear if cyclin D1 regulation results from a direct or indirect action of parafibromin. Nevertheless, parafibromin might represent a fruitful target for the development of future antineoplastic therapeutics. 
